Receptor News and Research

RSS

Study provides new knowledge about EphA2 receptor involved in several forms of cancer

Researchers at Karolinska Institutet in Sweden have headed a study that provides new knowledge about the EphA2 receptor, which is significant in several forms of cancer. This is important knowledge in itself - but just as important is how this study, which is published in the highly respected journal Nature Methods, was conducted.

8 Jul 2014

New technology in field of optogenetics can remotely control specific receptors by light

Institute for Basic Science (IBS), the main organization of the International Science and Business Belt project in South Korea, has announced that a group of researchers, led by professor Won Do Heo, have developed a new technology in the field of optogenetics that can remotely control specific receptors by light.

8 Jul 2014

$FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL$

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

7 Jul 2014

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).

7 Jul 2014

OHSU professor recognized with AAAS Martin and Rose Wachtel Cancer Research Award

Jeffrey Tyner, Ph.D., assistant professor of Cell, Developmental & Cancer Biology for Oregon Health & Science University (OHSU) and a researcher with OHSU's Knight Cancer Institute, has won a distinguished award from the American Association for the Advancement of Science (AAAS) for the development of a research program that more rapidly identifies the mutations driving a patient's cancer and accelerates development of precision treatments.

4 Jul 2014

Researchers unlock secret behind the activation of Ras proteins

A breakthrough discovery into how living cells process and respond to chemical information could help advance the development of treatments for a large number of cancers and other cellular disorders that have been resistant to therapy.

4 Jul 2014

Thyroxine may overcome mutated thyroid hormone receptor effects

Patients with a mutation in the thyroid hormone receptor α gene that affects both the thyroid hormone receptor α1 and α2 protein variants have similar characteristics to patients with mutations affecting only the α1 variant, report researchers.

3 Jul 2014

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to implement a clinical development plan, reinforcing its commitment to exploring new treatment options for rare diseases, as well as meeting the needs of all patients with skin diseases over the course of their lives.

2 Jul 2014

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Actavis plc today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

2 Jul 2014

Genentech agrees to acquire Seragon Pharmaceuticals

Genentech, a member of the Roche Group, today announced it has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc., a privately held biotechnology company based in San Diego, California.

2 Jul 2014

NEI researchers describe functions of gene responsible for anchoring cilia

Researchers at the National Eye Institute (NEI) have described the functions of a gene responsible for anchoring cilia - sensory hair-like extensions present on almost every cell of the body.

2 Jul 2014

New Tel Aviv University study finds link between Alzheimer's and brain hyperactivity

Patients with Alzheimer's disease run a high risk of seizures. While the amyloid-beta protein involved in the development and progression of Alzheimer's seems the most likely cause for this neuronal hyperactivity, how and why this elevated activity takes place hasn't yet been explained - until now.

1 Jul 2014

Genetic variants alter chance of sunitinib dose reduction

Scientists have identified genetic variants that reduce the likelihood of sunitinib dose reduction in patients with metastatic renal cell carcinoma.

30 Jun 2014

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years.

30 Jun 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

30 Jun 2014

Lassa virus uses two-step process to invade cells, shows study

Scientists have discovered that the Lassa virus, which is endemic to West Africa, uses an unexpected two-step process to enter cells.

28 Jun 2014

Researchers give new, unprecedented 3-D view of most important brain receptors

Researchers with Oregon Health & Science University's Vollum Institute have given science a new and unprecedented 3-D view of one of the most important receptors in the brain - a receptor that allows us to learn and remember, and whose dysfunction is involved in a wide range of neurological diseases and conditions, including Alzheimer's, Parkinson's, schizophrenia and depression.

28 Jun 2014

Researchers identify two classes of anti-depressants that reduce symptoms of depression

Depression is common in cancer, up to half of all patients facing the disease experience depressive symptoms, ranging from mild to severe. When depression co-exists with cancer, patients may be at an increased risk of death from cancer and from suicide.

28 Jun 2014

Researchers perform systematic review to identify best treatments for cancer-related depression

27 Jun 2014

Receptor News and Research

Study provides new knowledge about EphA2 receptor involved in several forms of cancer

New technology in field of optogenetics can remotely control specific receptors by light

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

OHSU professor recognized with AAAS Martin and Rose Wachtel Cancer Research Award

Researchers unlock secret behind the activation of Ras proteins

Thyroxine may overcome mutated thyroid hormone receptor effects

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Genentech agrees to acquire Seragon Pharmaceuticals

NEI researchers describe functions of gene responsible for anchoring cilia

New Tel Aviv University study finds link between Alzheimer's and brain hyperactivity

Genetic variants alter chance of sunitinib dose reduction

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

Lassa virus uses two-step process to invade cells, shows study

Researchers give new, unprecedented 3-D view of most important brain receptors

Researchers identify two classes of anti-depressants that reduce symptoms of depression

Researchers perform systematic review to identify best treatments for cancer-related depression

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News